Program
govorestat
Also written as “AT-007” and “Govorestat”.
Its studies are mostly in Charcot-Marie-Tooth Disease, led by Applied Therapeutics.
Furthest: phase 3, since Jul 14, 20205 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Applied Therapeutics | 50 open or running | phase 3since Jul 14, 2020 | Aug 23, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 23, 2019First study: phase 2 study in GalactosemiasFirst studyNCT04117711 · 114 enrolled · United States
- Jul 14, 2020Phase 3 study in GalactosemiasNCT04902781 · 47 enrolled · United States
- Feb 16, 2022Phase 3 study in GalactosemiasNCT05418829 · 7 enrolled · United States
- May 23, 2022Phase 3 study in Hereditary Neuropathy Caused by SORD DeficiencyNCT05397665 · 56 enrolled · United States, Czechia, Italy and more
- Sep 10, 2025Phase 3 study in Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD)NCT07191912 · United States, Australia, France and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07191912Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD) · United States, Australia, France and more | 3 | Withdrawn | Oct 2028 | 0 |
| NCT05397665Hereditary Neuropathy Caused by SORD Deficiency · United States, Czechia, Italy and more | 3 | Completed | Oct 12, 2024 | 56 |
| NCT05418829Galactosemias · United States | 3 | UNKNOWN | Nov 2022 | 7 |
| NCT04902781Galactosemias · United States | 3 | Completed | Mar 3, 2023 | 47 |
| NCT04117711Galactosemias · United States | 2 | Completed | Dec 14, 2021 | 114 |
How it is read
Names in the registry
- “AT-007”, 4 entries
- “Govorestat”, 1 entry
Conditions, from the studies’ own filings
- Charcot-Marie-Tooth Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.